XINT Stock Overview
A biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xintela AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.49 |
| 52 Week High | SEK 0.70 |
| 52 Week Low | SEK 0.20 |
| Beta | 2.11 |
| 1 Month Change | 40.00% |
| 3 Month Change | 25.64% |
| 1 Year Change | 95.22% |
| 3 Year Change | 0% |
| 5 Year Change | -87.11% |
| Change since IPO | -88.25% |
Recent News & Updates
Shareholder Returns
| XINT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 23.4% | 1.4% | 0.5% |
| 1Y | 95.2% | -2.7% | -3.6% |
Return vs Industry: XINT exceeded the Swedish Biotechs industry which returned -3.2% over the past year.
Return vs Market: XINT exceeded the Swedish Market which returned -3.6% over the past year.
Price Volatility
| XINT volatility | |
|---|---|
| XINT Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: XINT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: XINT's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Evy Lundgren-Åkerlund | www.xintela.se |
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
Xintela AB (publ) Fundamentals Summary
| XINT fundamental statistics | |
|---|---|
| Market cap | SEK 326.24m |
| Earnings (TTM) | -SEK 39.19m |
| Revenue (TTM) | SEK 4.22m |
Is XINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XINT income statement (TTM) | |
|---|---|
| Revenue | SEK 4.22m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 4.22m |
| Other Expenses | SEK 43.41m |
| Earnings | -SEK 39.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -929.77% |
| Debt/Equity Ratio | 0% |
How did XINT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 06:05 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xintela AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.